Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "BioNTech's"


11 mentions found


Pfizer-BioNTech's updated booster shot generates a stronger immune response against the omicron subvariants BA.4 and BA.5 compared with the original Covid vaccine, the companies said in a release Friday. Pfizer's original vaccine formula, which was first administered to older adults in December 2020, was designed to target the original coronavirus strain. The updated booster shot is designed to target the original virus strain, as well as BA.4 and BA.5, in a single shot. Two independent studies posted online late last month suggested that the updated shots do not offer better protection against the new omicron subvariants than the original vaccines do. The new findings may hint that the updated booster is better than the original vaccine, but not by much, said John Moore, a professor of microbiology and immunology at Weill Cornell Medical College.
SINGAPORE—China agreed to approve BioNTech SE’s Covid-19 vaccines for foreign residents, German Chancellor Olaf Scholz said in Beijing Friday, in what would mark the first approval of an mRNA vaccine for Covid-19 for use in China. Mr. Scholz and Chinese leader Xi Jinping also discussed a pathway for approving the BioNTech vaccine for the broader population in China, Mr. Scholz said in a news conference, suggesting that regulators at the European Medicines Agency would be involved.
SINGAPORE—China agreed to approve BioNTech SE’s Covid-19 vaccines for foreign residents, German Chancellor Olaf Scholz said in Beijing Friday, in what would mark the first mRNA vaccine for Covid-19 approved for use in China. Mr. Scholz and Chinese leader Xi Jinping also discussed a pathway for approving the BioNTech Covid vaccine for the broader population in China, Mr. Scholz said in a news conference, suggesting that regulators at the European Medicines Agency would be involved.
After all, Chinese officials have not announced an official transition away from their very strict Covid policy. Nevertheless, the moves in certain stocks tied to China — including many owned by the Club — show the market is taking the vaccine policy change in stride. The cosmetics giant has a big China business and just a few days ago it cut its sales guidance partly due to China's Covid policy. The price move provided some support for oil stocks in Friday's volatile stock market. It's not immediately clear when expatriates in China could actually start getting a shot of the BioNTech-Pfizer Covid vaccine.
It is very premature, in my view, to think about or be talking about pausing our rate hikes. The news sent those stocks reliant on China for growth — Starbucks, Estee Lauder and Wynn Resorts, among many others — higher. Or bad news could just be bad news if weak data signals a recession ahead. And good news could be good news: for example, if China reopens and U.S. companies exposed to the region see a boost in demand. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
[1/2] A medical worker holds a vial of the "Comirnaty" Pfizer-BioNTech COVID-19 vaccine at a coronavirus disease (COVID-19) vaccination center in Nice, France, December 1, 2021. REUTERS/Eric Gaillard/File PhotoOct 28 (Reuters) - A European Medicines Agency (EMA) committee on Friday recommended adding heavy menstrual bleeding to the list of side effect of mRNA COVID-19 vaccines made by Moderna (MRNA.O), as well as Pfizer (PFE.N) and its partner BioNTech (22UAy.DE). The regulator has now concluded that there is at least a "reasonable possibility" that heavy menstrual bleeding is causally associated with these vaccines. Menstrual disorders can occur due to a range of reasons, including underlying medical conditions as well as stress and tiredness. Health authorities have highlighted that cases have also been reported following COVID-19 infection.
The authorization of Novavax's booster could significantly increase the role that its shot plays in U.S. vaccination efforts. The Centers for Disease Control and Prevention still has to give the final go ahead before pharmacies can start administering Novavax's booster. Only 35,300 people have received Novavax's shots so far in the U.S., according to data from the CDC. By comparison, some 372.5 million Pfizer shots, 235.8 million Moderna doses and 18.9 million Johnson & Johnson shots have been administered across the U.S. so far. People who received Novavax's vaccine as their primary series are also eligible for Pfizer and BioNTech's new omicron booster.
If you already got your omicron-specific Covid booster, you might have experienced some side effects. But there's no need to worry: Experts and new data say the new shots appear to work — regardless of whether you experience moderate, mild or no side effects at all. The new boosters gained approval from the U.S. Food and Drug Administration and the CDC before they finished clinical trials. Like previous Covid vaccines, the new boosters are designed to help you fight the virus by triggering an immune response in your body. Covid vaccines typically take two to three weeks to fully ramp up your immunity, which can help your body stop an infection from happening or keep it from progressing to severe disease.
The Food and Drug Administration on Wednesday authorized updated Covid booster shots that target the omicron variant of the virus for young children. The decision will now go to the Centers for Disease Control and Prevention, which could issue its final recommendation on the updated shots within hours. Only about 31% of children ages 5 to 11 have received two doses of any Covid vaccine, according to CDC data. Experts say it's important for people to receive the updated shots because the nation could face yet another potential wave of Covid infections this winter. The boosters are important because data has shown that any Covid vaccine greatly decreases the risk of severe outcomes from the virus, said O’Leary.
Oct 12 (Reuters) - U.S. health regulators authorized the use of Omicron-tailored COVID-19 booster shots from Moderna Inc (MRNA.O) and Pfizer Inc (PFE.N) in children as young as 5, a move that will expand the government's fall vaccination campaign. The U.S. Food and Drug Administration on Wednesday green-lighted Moderna's bivalent vaccine for those aged six and above, while Pfizer's updated shot was authorized in children aged five and above. The U.S. Centers for Disease Control and Prevention also backed the FDA's authorization, clearing the way for the shots to be administered in children. Overall, COVID-19 vaccination rates in the United States have stayed low among kids, with nearly 40% of children aged 5-11 vaccinated with one dose of a vaccine so far. Around 11.5 million people received the updated shots over the first five weeks of the rollout last month, which represents just 5.4% of the people aged 12 or older who are eligible to receive them.
U.S. CDC expects Omicron COVID boosters for kids by mid-October
  + stars: | 2022-09-21 | by ( ) www.reuters.com   time to read: +1 min
REUTERS/Hannah BeierSept 21 (Reuters) - The U.S. Centers for Disease Control and Prevention expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October. Register now for FREE unlimited access to Reuters.com RegisterThe CDC said it expects Pfizer-BioNTech's (PFE.N), bivalent vaccine to be available for children aged 5-11 years, and Moderna's (MRNA.O) vaccine for those aged 6-17 years, pending FDA authorization. The Pfizer vaccine is already authorized as a booster dose for children over 12 years of age, while Moderna's bivalent vaccine is authorized for adults. The CDC expects pre-orders for the Pfizer shot to begin for the age group next week. The Moderna vaccine will have the same formulation for children and adults and will not require a separate pre-order period, the CDC said.
Total: 11